Escitalopram Tablets - FDA prescribing information, side effects and uses. Major Depressive Disorder. Escitalopram Tablets are indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 1. It must be associated with at least 3 of the following symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. Escitalopram Tablets Dosage and Administration. Escitalopram Tablets should be administered once daily, in the morning or evening, with or without food. ![]() Major Depressive Disorder. Initial Treatment. ![]() Adolescents. The recommended dose of Escitalopram Tablets is 1. A flexible- dose trial of Escitalopram Tablets (1. Escitalopram Tablets . If the dose is increased to 2. Adults. The recommended dose of Escitalopram Tablets is 1. A fixed- dose trial of Escitalopram Tablets demonstrated the effectiveness of both 1. Escitalopram Tablets, but failed to demonstrate a greater benefit of 2. If the dose is increased to 2. Maintenance Treatment. It is generally agreed that acute episodes of major depressive disorder require several months or longer of sustained pharmacological therapy beyond response to the acute episode. Systematic evaluation of continuing Escitalopram Tablets 1. Escitalopram Tablets during an 8- week, acute- treatment phase demonstrated a benefit of such maintenance treatment . Nevertheless, the physician who elects to use Escitalopram Tablets for extended periods should periodically re- evaluate the long- term usefulness of the drug for the individual patient. Patients should be periodically reassessed to determine the need for maintenance treatment. Escitalopram 5mg, 10mg, 20mg Film-coated Tablets - Patient Information Leaflet (PIL) by Actavis UK Ltd. Escitalopram Tablets official prescribing information for healthcare professionals. Includes: indications, dosage, adverse reactions, pharmacology and more. Generalized Anxiety Disorder. Initial Treatment. Adults. The recommended starting dose of Escitalopram Tablets is 1. If the dose is increased to 2. Maintenance Treatment. Generalized anxiety disorder is recognized as a chronic condition. ![]() The efficacy of Escitalopram Tablets in the treatment of GAD beyond 8 weeks has not been systematically studied. The physician who elects to use Escitalopram Tablets for extended periods should periodically re- evaluate the long- term usefulness of the drug for the individual patient. Special Populations. No dosage adjustment is necessary for patients with mild or moderate renal impairment. Escitalopram Tablets should be used with caution in patients with severe renal impairment. Discontinuation of Treatment with Escitalopram Tablets. Symptoms associated with discontinuation of Escitalopram Tablets and other SSRIs and SNRIs have been reported . Patients should be monitored for these symptoms when discontinuing treatment. A gradual reduction in the dose rather than abrupt cessation is recommended whenever possible. ![]() Escitalopram (Lexapro, Cipralex, Esertia) Escitalopram is a highly selective serotonin reuptake inhibitor (SSRI) used to treat depression and anxiety. Some antidepressants can have an effect on your appetite. Read about Lexapro’s effects and how they relate to weight. Lexapro (Escitalopram) is prescribed to treat depression and generalized anxiety disorder, the constant excessive worrying that interferes with daily life. Teva-Escitalopram: Escitalopram belongs to the group of medications called selective serotonin reuptake inhibitors (SSRIs). It is used to treat depression, obsessive. If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose but at a more gradual rate. Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) Intended to Treat Psychiatric Disorders. At least 1. 4 days should elapse between discontinuation of an MAOI intended to treat psychiatric disorders and initiation of therapy with escitalopram tablets. Conversely, at least 1. MAOI intended to treat psychiatric disorders . In a patient who requires more urgent treatment of a psychiatric condition, other interventions, including hospitalization, should be considered . If acceptable alternatives to linezolid or intravenous methylene blue treatment are not available and the potential benefits of linezolid or intravenous methylene blue treatment are judged to outweigh the risks of serotonin syndrome in a particular patient, escitalopram tablets should be stopped promptly, and linezolid or intravenous methylene blue can be administered. The patient should be monitored for symptoms of serotonin syndrome for 2 weeks or until 2. Therapy with escitalopram tablets may be resumed 2. The clinician should, nevertheless, be aware of the possibility of emergent symptoms of serotonin syndrome with such use . The use of escitalopram tablets within 1. MAOI intended to treat psychiatric disorders are also contraindicated . Suicide is a known risk of depression and certain other psychiatric disorders, and these disorders themselves are the strongest predictors of suicide. There has been a long- standing concern, however, that antidepressants may have a role in inducing worsening of depression and the emergence of suicidality in certain patients during the early phases of treatment. Pooled analyses of short- term placebo- controlled trials of antidepressant drugs (SSRIs and others) showed that these drugs increase the risk of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults (ages 1. MDD) and other psychiatric disorders. Short- term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 2. The pooled analyses of placebo- controlled trials in children and adolescents with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders included a total of 2. The pooled analyses of placebo- controlled trials in adults with MDD or other psychiatric disorders included a total of 2. There was considerable variation in risk of suicidality among drugs, but a tendency toward an increase in the younger patients for almost all drugs studied. There were differences in absolute risk of suicidality across the different indications, with the highest incidence in MDD. The risk differences (drug vs. These risk differences (drug- placebo difference in the number of cases of suicidality per 1. Table 1. TABLE 1. Age Range. Drug- Placebo Difference in Numberof Cases of Suicidality per 1. Patients Treated Increases Compared to Placebo< 1. Decreases Compared to Placebo. There were suicides in the adult trials, but the number was not sufficient to reach any conclusion about drug effect on suicide. It is unknown whether the suicidality risk extends to longer- term use, i. However, there is substantial evidence from placebo- controlled maintenance trials in adults with depression that the use of antidepressants can delay the recurrence of depression. All patients being treated with antidepressants for any indication should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases. The following symptoms, anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (psychomotor restlessness), hypomania, and mania, have been reported in adult and pediatric patients being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Although a causal link between the emergence of such symptoms and either the worsening of depression and/or the emergence of suicidal impulses has not been established, there is concern that such symptoms may represent precursors to emerging suicidality. Consideration should be given to changing the therapeutic regimen, including possibly discontinuing the medication, in patients whose depression is persistently worse, or who are experiencing emergent suicidality or symptoms that might be precursors to worsening depression or suicidality, especially if these symptoms are severe, abrupt in onset, or were not part of the patient's presenting symptoms. If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms . Such monitoring should include daily observation by families and caregivers . Prescriptions for escitalopram oxalate should be written for the smallest quantity of tablets consistent with good patient management, in order to reduce the risk of overdose. Screening Patients for Bipolar Disorder. A major depressive episode may be the initial presentation of bipolar disorder. It is generally believed (though not established in controlled trials) that treating such an episode with an antidepressant alone may increase the likelihood of precipitation of a mixed/manic episode in patients at risk for bipolar disorder. Whether any of the symptoms described above represent such a conversion is unknown. However, prior to initiating treatment with an antidepressant, patients with depressive symptoms should be adequately screened to determine if they are at risk for bipolar disorder; such screening should include a detailed psychiatric history, including a family history of suicide, bipolar disorder, and depression. It should be noted that escitalopram oxalate is not approved for use in treating bipolar depression. Serotonin Syndrome. The development of a potentially life- threatening serotonin syndrome has been reported with SNRIs and SSRIs, including escitalopram oxalate, alone but particularly with concomitant . John’s Wort) and with drugs that impair metabolism of serotonin (in particular, MAOIs, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue). Serotonin syndrome symptoms may include mental status changes (e. Patients should be monitored for the emergence of serotonin syndrome. The concomitant use of escitalopram oxalate with MAOIs intended to treat psychiatric disorders is contraindicated. Escitalopram oxalate should also not be started in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
November 2017
Categories |